Smilagenin
Code | Size | Price |
---|
TAR-T4954L-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T4954L-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Smilagenin is an orally active inducer of nonpeptide neurotrophic factor. It also prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons, and by MPTP in a mouse model of Parkinson's disease.
CAS:
126-18-1
Formula:
C27H44O3
Molecular Weight:
416.646
Purity:
0.98
SMILES:
[H][C@]12C[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@@H](O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]1(CC[C@@H](C)CO1)O2
References
Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008 Jul;22(7):2488-97. doi: 10.1096/fj.07-095398. Epub 2008 Mar 25. PubMed PMID: 18364399.
Lim SM, Jeong JJ, Kang GD, Kim KA, Choi HS, Kim DH. Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-?B and MAPK activation and restoring Th17/Treg cell balance. Int Immunopharmacol. 2015 Apr;25(2):493-503. doi: 10.1016/j.intimp.2015.02.016. Epub 2015 Feb 16. PubMed PMID: 25698557.
Li J, Xia Z, Sun X, Zhang R, Huang G, Hickling R, Xia Z, Hu Y, Zhang Y. Reversal of dopamine neurons and locomotor ability degeneration in aged rats with smilagenin. Neuroscience. 2013 Aug 15;245:90-8. doi: 10.1016/j.neuroscience.2013.04.028. Epub 2013 Apr 23. PubMed PMID: 23624370.
Athauda D, Foltynie T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol. 2015 Jan;11(1):25-40. doi: 10.1038/nrneurol.2014.226. Epub 2014 Dec 2. Review. PubMed PMID: 25447485.